These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26515417)

  • 1. Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
    Thomas MR; Outteridge SN; Ajjan RA; Phoenix F; Sangha GK; Faulkner RE; Ecob R; Judge HM; Khan H; West LE; Dockrell DH; Sabroe I; Storey RF
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2562-70. PubMed ID: 26515417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of P2Y12 inhibitors on inflammation and immunity.
    Thomas MR; Storey RF
    Thromb Haemost; 2015 Aug; 114(3):490-7. PubMed ID: 26156883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
    Kiers D; van der Heijden WA; van Ede L; Gerretsen J; de Mast Q; van der Ven AJ; El Messaoudi S; Rongen GA; Gomes M; Kox M; Pickkers P; Riksen NP
    Thromb Haemost; 2017 Aug; 117(9):1798-1807. PubMed ID: 28692111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
    Traby L; Kollars M; Kaider A; Eichinger S; Wolzt M; Kyrle PA
    J Thromb Haemost; 2016 Feb; 14(2):273-81. PubMed ID: 26663880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
    Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
    J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.
    Schrottmaier WC; Kral JB; Badrnya S; Assinger A
    Thromb Haemost; 2015 Aug; 114(3):478-89. PubMed ID: 25904241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of P2Y
    Zhang Y; Zhang S; Ding Z
    Adv Exp Med Biol; 2017; 906():307-324. PubMed ID: 27628007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
    Reiner MF; Akhmedov A; Stivala S; Keller S; Gaul DS; Bonetti NR; Savarese G; Glanzmann M; Zhu C; Ruf W; Yang Z; Matter CM; Lüscher TF; Camici GG; Beer JH
    Cardiovasc Res; 2017 Jan; 113(1):61-69. PubMed ID: 28028070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and clinical use of prasugrel and ticagrelor.
    Ahmad S; Storey RF
    Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 Diabetes and ADP Receptor Blocker Therapy.
    Samoš M; Fedor M; Kovář F; Mokáň M; Bolek T; Galajda P; Kubisz P; Mokáň M
    J Diabetes Res; 2016; 2016():6760710. PubMed ID: 26824047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
    Tam CC; Kwok J; Wong A; Yung A; Shea C; Kong SL; Tang WH; Siu D; Chan R; Lee S
    J Int Med Res; 2017 Feb; 45(1):134-146. PubMed ID: 28222641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
    Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
    Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
    Brice AE; Hernandez GA; Sanchez M; Haynick M; Mendoza CE
    Platelets; 2017 May; 28(3):305-309. PubMed ID: 27778525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
    Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
    J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.